Financial Performance - Total revenue for the year ended December 31, 2025, was HKD 117,397,000, a decrease of 25.4% compared to HKD 157,235,000 in 2024[2] - Gross profit for 2025 was HKD 51,496,000, down 47.7% from HKD 98,344,000 in 2024[2] - The company reported a profit before tax of HKD 82,184,000, a significant recovery from a loss of HKD 175,157,000 in the previous year[2] - Net profit for the year was HKD 82,809,000, compared to a loss of HKD 174,286,000 in 2024[2] - Basic and diluted earnings per share for 2025 were HKD 0.3595, a turnaround from a loss of HKD 0.7565 per share in 2024[3] - The group reported a total external segment revenue of HKD 117,397,000 for 2025, compared to HKD 157,235,000 in 2024, indicating a decline of 25.3%[18] - The group’s net profit before tax for 2025 was HKD 82,184,000, a significant recovery from a loss of HKD 175,157,000 in 2024[18] - The group recorded a profit of approximately HKD 82,800,000 for the year ended December 31, 2025, compared to a loss of HKD 174,300,000 in 2024, primarily due to a reversal of impairment losses on receivables amounting to approximately HKD 50,900,000[47] Assets and Liabilities - Total assets decreased to HKD 538,470,000 in 2025 from HKD 754,717,000 in 2024, reflecting a reduction of 28.7%[4] - Current liabilities decreased to HKD 255,760,000 in 2025 from HKD 512,763,000 in 2024, a reduction of 50.1%[4] - The company's total equity increased to HKD 333,659,000 in 2025 from HKD 249,252,000 in 2024, representing a growth of 33.9%[5] - The company has no non-current liabilities related to bonds in 2025, compared to HKD 50,000,000 in 2024[5] - The group’s total assets as of December 31, 2025, amounted to HKD 602,220,000, down from HKD 824,714,000 in 2024, a decrease of 27%[22] - The total liabilities as of December 31, 2025, were HKD 268,561,000, compared to HKD 575,462,000 in 2024, reflecting a reduction of 53.3%[22] - The total trade payables amounted to HKD 38,656,000, an increase from HKD 27,530,000 in 2024[38] Revenue Breakdown - Revenue from medical products increased to HKD 78,544,000 in 2025 from HKD 72,234,000 in 2024, representing an increase of 4.5%[12] - Total revenue from customer contracts for 2025 was HKD 84,406,000, up from HKD 77,782,000 in 2024, marking a growth of 8.3%[12] - The group’s total revenue from the securities brokerage and asset management services segment was HKD 1,768,000 in 2025, down from HKD 3,907,000 in 2024, a decrease of 54.8%[18] - The group’s total revenue from lending and other financial services was HKD 31,893,000 in 2025, compared to HKD 76,607,000 in 2024, a decline of 58%[18] - Revenue from Hong Kong for 2025 is HKD 100,001,000, slightly up from HKD 99,872,000 in 2024[24] - Revenue from Europe dropped significantly from HKD 46,723,000 in 2024 to HKD 10,792,000 in 2025, a decline of 76.9%[24] Cash Flow and Investments - As of December 31, 2025, the company's cash and cash equivalents decreased by approximately HKD 32,800,000 to about HKD 58,300,000 compared to HKD 91,100,000 as of December 31, 2024[48] - The company sold a total of 1,560,000 shares of a subsidiary on January 12, 2026, for approximately HKD 3,300,000, expecting a realizable gain of about HKD 200,000[56] - The company did not have any pledged assets as of December 31, 2025[50] Employee and Governance - The total number of employees decreased to 101 as of December 31, 2025, from 149 in the previous year[54] - The company maintained compliance with the corporate governance code throughout the year ended December 31, 2025[61] Dividends and Provisions - The company did not recommend a final dividend for the year ending December 31, 2025, consistent with 2024[30] - The board did not recommend the distribution of a final dividend for the year ended December 31, 2025, consistent with the previous year[55] - The company’s tax provision for the current year in China was HKD 81,000, down from HKD 397,000 in 2024[28] Risk and Strategy - The group faced credit concentration risk as 62% of all loans to margin clients were from the top five margin clients[36] - The company plans to continue its focus on investment holding and may explore new strategies for market expansion and product development in the future[6] - The group plans to focus on expanding its financial services, including corporate financing and asset management, amid a challenging economic environment[45]
隆成金融(01225) - 2025 - 年度业绩